Boehringer Ingelheim – Talk Bio

Actionable Insights Powered by AI

LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

1 week ago talkbio0Tagged Boehringer Ingelheim, Drug licensing, Generalized pustular psoriasis, IL1RAP protein, human, Immunology, News [Publication Type], Partnership, Pharma, Psoriasis, spesolimab, Spevigo

LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news

Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Biological Markers, Boehringer Ingelheim, Cancer Research, Discover, Drug Development, Neoplasms, real-world data, strategic collaboration, Tempus AI

Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration

Boehringer Ingelheim’s Iclepertin Fails to Meet Primary and Secondary Endpoints in Phase III Schizophrenia Trials

6 months ago talkbio0Tagged Boehringer Ingelheim, CONNEX, Iclepertin, Impaired cognition, Phase 3 Clinical Trials, Programs - Publication Format, Schizophrenia

Boehringer Ingelheim, iclepertin, schizophrenia, Phase III trials, cognitive impairment, CONNEX program

Boehringer Ingelheim Discontinues NPY2 Obesity Drug Development with Gubra, Focuses on Triple-Agonist Candidate

9 months ago talkbio0Tagged BI, Boehringer Ingelheim, Clinical Trials, Gubra, NPY2, Obesity

Boehringer Ingelheim, Gubra, obesity drug, NPY2, triple-agonist, BI 3034701, clinical trials